Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
634789
European Union's Horizon 2020 research and innovation program under grant agreement No 634789 - 'Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time'.
Amgen Limited
Celgene International
Janssen Pharmaceuticals
Novartis Pharmacy B.V. Oncology Europe
Takeda Pharmaceuticals International
PubMed
36335984
DOI
10.1111/bjh.18542
Knihovny.cz E-zdroje
- Klíčová slova
- causes of death, myelodysplastic syndromes, relative survival,
- MeSH
- akutní myeloidní leukemie * MeSH
- kardiovaskulární nemoci * MeSH
- lidé MeSH
- myelodysplastické syndromy * MeSH
- příčina smrti MeSH
- progrese nemoci MeSH
- registrace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic
Department of Haematology Aarhus University Hospital Aarhus Denmark
Department of Haematology Aberdeen Royal Infirmary Aberdeen UK
Department of Hematology Radboud University Medical Center Nijmegen the Netherlands
Department of Internal Medicine 5 Innsbruck Medical University Innsbruck Austria
Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden
Department of Medicine Division of Hematology University of Patras Medical School Patras Greece
Epidemiology and Cancer Statistics Group Department of Health Sciences University of York York UK
Service d'Hématologie Centre Hospitalier de Perpignan Perpignan France
Service d'Hématologie Centre Hospitalier Universtaire Brabois Vandoeuvre Nancy France
St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK
Zobrazit více v PubMed
Greenberg BP, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-88.
Greenberg PL, Tuechler H. Revised international prognostic scoring system for MDS. Blood. 2012;120:2454-65.
de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372-83.
Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95:937-44.
Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116:2174-9.
Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, et al. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017;1:2032-40.
Polednak AP. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: utility of multiple causes of death in surveillance. Cancer Epidemiol. 2013;37:569-74.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377, 111-121.
Maynadié M, de Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98:230-8.
Roman E, Smith A, Appleton S, Crouch S, Kelly R, Kinsey S, et al. Myeloid malignancies in the real-world: occurrence, progression and survival in the UK's population-based Haematological malignancy research network 2004-15. Cancer Epidemiol. 2016;42:186-98.
Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96:441-9.
Jaffe ES, Harris NL, Stein H, Vardiman J. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, Oxford University Press; 2001.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-405.
Di Carlo V, Rachet B, Bannon F, Woods LM, Maringe C, Bonaventure A, et al. (2020) Life tables for the CONCORD programme.
Morel et al. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of the age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Hem. 1996;94:116-9.
Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. 116, 2174-2179. https://doi.org/10.1002/cncr.24984
Cordoba I, Gonzalez-Porras JR, Such E, Nomdedeu B, Luño E, de Paz R, et al. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res. 2012;36:287-92.
Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, et al. Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: a SEER-medicare analysis. Leukemia. 2020;34:1689-93.
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847-52.
Merz A, Germing U, Kobbe G, Kaivers J, Jauch A, Radujkovic A, et al. EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J. 2019;9:85.
Jeong HY, Kang WS, Hong MH, Jeong HC, Shin MG, Jeong MH, et al. 5-azacytidine modulates interferon regulatory factor 1 in macrophages to exert a cardioprotective effect. Sci Rep. 2015;5:1-13.
